X0306 4 2020-05-08 0 0001551152 AbbVie Inc. ABBV 0001811896 Strom Carrie C 1 N. WAUKEGAN ROAD NORTH CHICAGO IL 60064 0 1 0 0 SVP & Pres Global Allerg Aesth Common Stock, $0.01 par value 2020-05-08 4 A 0 2439 A 2439 D Common Stock, $0.01 par value 2020-05-08 4 A 0 37903 A 40342 D Common Stock, $0.01 par value 2020-05-11 4 A 0 23196 0 A 63538 D Option (right to buy) 41.39 2020-05-08 4 A 0 4184 0 A 2020-05-08 2021-08-05 Common Stock 4184 4184 D Option (right to buy) 47.27 2020-05-08 4 A 0 4184 0 A 2020-05-08 2022-02-17 Common Stock 4184 4184 D Option (right to buy) 56.93 2020-05-08 4 A 0 7809 0 A 2020-05-08 2023-02-21 Common Stock 7809 7809 D Option (right to buy) 67.25 2020-05-08 4 A 0 6370 0 A 2020-05-08 2024-02-21 Common Stock 6370 6370 D Option (right to buy) 125.82 2020-05-08 4 A 0 5729 0 A 2020-05-08 2025-02-20 Common Stock 5729 5729 D Option (right to buy) 133.53 2020-05-08 4 A 0 2017 0 A 2020-05-08 2025-03-16 Common Stock 2017 2017 D Option (right to buy) 123.51 2020-05-08 4 A 0 2567 0 A 2020-05-08 2026-03-07 Common Stock 2567 2567 D Option (right to buy) 104.04 2020-05-08 4 A 0 3440 0 A 2027-03-06 Common Stock 3440 3440 D Option (right to buy) 65.45 2020-05-08 4 A 0 3613 0 A 2028-03-06 Common Stock 3613 3613 D Received in exchange for 2,816 shares of Allergan plc common stock in connection with its acquisition by AbbVie Inc. Allergan shareholders received 0.8660 AbbVie shares for each Allergan share (based on the closing price of AbbVie's common stock of $84.22 on May 7, 2020). Received in exchange for 16,457 restricted stock units of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. restricted stock units was calculated pursuant to an equity award conversion ratio of 2.303. The restricted stock units vest as follows: 5,194 on 12/31/2020; 1,633 on 3/2/2021; 903 on 3/5/2021; 717 on 3/6/2021; 247 on 3/7/2021; 470 on 5/7/2021; 20,844 on 12/31/2021; 1,633 on 3/2/2022; 903 on 3/5/2022; 716 on 3/6/2022; 470 on 5/7/2022; 1,633 on 3/2/2023; 905 on 3/5/2023; and 1,635 on 3/2/2024. These securities represent restricted stock units granted under the AbbVie 2013 Incentive Stock Program. They vest in four equal annual increments on the date of grant and include the right to have stock withheld for tax purposes. The options are exercisable as follows: 2,579 exercisable as of 5/8/2020 and 861 as of 3/7/2021. Received in exchange for stock options of Allergan plc in connection with the acquisition of Allergan plc by AbbVie Inc. and previously issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc. The number of AbbVie Inc. stock options was calculated pursuant to an equity award conversion ratio of 2.303. The options are exercisable as follows: 2,579 exercisable as of 5/8/2020 and 861 as of 3/7/2021. The options are exercisable as follows: 1,804 exercisable as of 5/8/2020; 902 as of 3/6/2021; and 907 as of 3/6/2022. Steven L. Scrogham, attorney-in-fact for Carrie Strom 2020-05-12